97963-58-1 Usage
Chemical core
1H-Benzimidazole
A heterocyclic aromatic ring system consisting of a central nitrogen atom bonded to two carbon atoms, with one additional carbon atom attached to the nitrogen.
Fluoromethoxy group
5-(difluoromethoxy)
A methoxy group (-OCH3) with two hydrogen atoms replaced by fluorine atoms (-CF2H), attached to the benzimidazole core at the 5-position.
Methoxy group
6-methoxy
An oxygen atom bonded to a methyl group (-OCH3), attached to the benzimidazole core at the 6-position.
Thiomethyl group
2-[[(4-methoxy-3-methyl-2-pyridinyl)methyl]thio]-
A sulfur atom bonded to a methyl group (-CH3), attached to the benzimidazole core at the 2-position through a pyridinylmethyl group.
Pyridinylmethyl group
2-[[(4-methoxy-3-methyl-2-pyridinyl)methyl]thio]-
A methyl group (-CH3) bonded to a 2-pyridinyl ring system, which is further substituted with a methoxy group at the 4-position and a methyl group at the 3-position.
Potential applications
Pharmaceuticals
Benzimidazole compounds are known for their diverse pharmacological activities, such as anti-cancer and anti-inflammatory properties.
Unique biological activities
Specific substitution pattern
The combination of fluoromethoxy, methoxy, thiomethyl, and pyridinylmethyl groups in 1H-Benzimidazole,
5-(difluoromethoxy)-6-methoxy-2-[[(4-methoxy-3-methyl-2-pyridinyl)meth
yl]thio]- may contribute to its distinct biological activities and potential therapeutic use.
Check Digit Verification of cas no
The CAS Registry Mumber 97963-58-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,7,9,6 and 3 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 97963-58:
(7*9)+(6*7)+(5*9)+(4*6)+(3*3)+(2*5)+(1*8)=201
201 % 10 = 1
So 97963-58-1 is a valid CAS Registry Number.
97963-58-1Relevant academic research and scientific papers
(H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate
Kohl,Sturm,Senn-Bilfinger,Simon,Kruger,Schaefer,Rainer,Figala,Klemm
, p. 1049 - 1057 (2007/10/02)
[(Pyridylmethyl)sulfinyl]benzimidazoles 1 (PSBs) are a class of highly potent antisecretory (H+,K+)-ATPase inhibitors which need to be activated by acid to form their active principle, the cyclic sulfenamide 4. Selective inhibitors of the (H+,K+)-ATPase in vivo give rise to the nonselective thiophile 4 solely at low pH, thus avoiding interaction with other thiol groups in the body. The propensity to undergo the acid-catalyzed transformation is dependent on the nucleophilic/electrophilic properties of the functional groups involved in the formation of 2 since this step is both rate-determining and pH-dependent. The aim of this study was to identify compounds with high (H+,K+)-ATPase inhibitory activity in stimulated gastric glands possessing acidic pH, but low reactivity (high chemical stability) at neutral pH as reflected by in vitro (Na+,K+)-ATPase inhibitory activity. The critical influence of substituents flanking the pyridine 4-methoxy substituent present in all derivatives was carefully studied. The introduction of a 3-methoxy group gave inhibitors possessing a combination of high potency, similar to omeprazole and lansoprazole, but increased stability. As a result of these studies, compound 1a (INN pantoprazole) was selected as a candidate drug and is currently undergoing phase III clinical studies.
